Robert Kiyosaki: The GOP Tax Cut Won't Boost Savings
Entrepreneur and author of "Rich Dad Poor Dad," Robert Kiyosaki joined Cheddar to discuss his views on why the rich are getting richer!
The businessman explains that the lack of financial education in schools is a major contributor to the poor paying higher taxes. Kiyosaki says that people like himself and President Trump are rich and many others are not, because of financial literacy.
The less one knows about how to use debt and other tax-related loopholes, the more likely you are to end up paying more.
When asked about former co-author and president, Donald Trump's proposed tax cuts, he says he doesn't believe it's going to put more money back into the average person's wallet.
On the other hand, charity investments, knowledge of tax exemptions, and the likes, are rich people's way around paying taxes. He cites the system as unfair, but says someone has to pay taxes, an onus usually placed on the poor.
When it comes to charitable giving, Kiyosaki explains that a charitable remainder trust is a way to manage how your tax money is distributed. He says that charity is an essential part of being human, and people should prioritize giving to charity before paying off any debt you have.
Kiyosaki said that if he were to die today, his charitable remainder trust is set to give back $35 million yearly in perpetuity, to the causes he cares about.
The health and wellness industry is booming, expected to hit $14 trillion by 2032. Equinox teamed up with Function Health to revolutionize health optimization.
Featherie, a line of sustainable and functional golf wear for girls, fills a void in the market, catering to the increasing number of female junior golfers.
The CEO of LiveOne, Rob Ellin, discusses the DOJ's lawsuit against Live Nation and Ticketmaster, how will if affect you and the future of live events. Watch!
Nvidia did a record $26 billion in sales in the latest quarter. And get ready for the stock to keep climbing, because the A.I. boom is just getting started.
In honor of National Cancer Research Month, Perspective Therapeutics discusses its latest treatment — currently in clinical trials — that targets cancer cells d